Durect Corp
DRRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$59.31M
Close$
$0.12
93.7% downside
Current Fair Value
93.7% downsideOvervalued by 93.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $59.31 Million |
|---|---|
| Enterprise Value | $55.53 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.27 |
| Beta | 0.93 |
| Outstanding Shares | 31,042,000 |
Return
| Return on Equity | -88.34% |
|---|---|
| Return on Assets | -27.86% |
| Return on Invested Capital | -326.72% |
Valuation & Multiples
| P/E Ratio | 73.47 |
|---|---|
| PEG | -189.43 |
| Price to Sales | -1.91 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -35.42 |
| Enterprise Value to EBIT | -3.7 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 0.42% |
|---|---|
| Total Calls | 17,900▼ 74.89% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 22.51%▲ 1.33% |
|---|---|
| Total Invested | $4.44M▼ 15.83% |
| Investors Holding | 41▲ 1.00% |
ESG Score
No data
About Durect Corp
CEO: James Brown DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. ...